Contrasting Zura Bio (NASDAQ:ZURA) & Viva Biotech (OTCMKTS:VBIZF)

Viva Biotech (OTCMKTS:VBIZF) and Zura Bio (NASDAQ:ZURA) are both healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, institutional ownership, dividends, risk, earnings, profitability and valuation.

Analyst Ratings

This is a summary of recent ratings and price targets for Viva Biotech and Zura Bio, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Viva Biotech	0	0	0	0	0.00
Zura Bio	1	1	4	1	2.71

Zura Bio has a consensus target price of $10.75, suggesting a potential upside of 81.16%. Given Zura Bio’s stronger consensus rating and higher possible upside, analysts clearly believe Zura Bio is more favorable than Viva Biotech.

Insider & Institutional Ownership

61.1% of Zura Bio shares are held by institutional investors. 12.4% of Zura Bio shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Valuation and Earnings

This table compares Viva Biotech and Zura Bio”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Viva Biotech	N/A	N/A	N/A	N/A	N/A
Zura Bio	N/A	N/A	-$99.35 million	($1.09)	-5.44

Profitability

This table compares Viva Biotech and Zura Bio’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Viva Biotech	N/A	N/A	N/A
Zura Bio	N/A	-55.74%	-48.07%

Summary

Zura Bio beats Viva Biotech on 6 of the 8 factors compared between the two stocks.

About Viva Biotech

Viva Biotech Holdings, an investment holding company, engages in the provision of structure-based drug discovery services to biotechnology and pharmaceutical customers worldwide. The company provides discovery biology services, including protein expression and purification, structural biology, hit discovery, bioassay, biomolecular interaction, and pharmacokinetics; chemistry services, such as medicinal and synthetic chemistry, analytical chemistry, purification preparation, and computer-aided drug design services, as well as offers chemical technology platforms; and antibody/biologics research and development services comprising recombinant protein expression platform, antibody discovery and affinity maturation, assay platform, antibody production and identification platform, and antigen-antibody structural resolution platform solutions. It also offers PROTAC/molecular glue services, including protein preparation and ternary complex structure determination, screening for molecule glues and novel E3 ligase ligands, PROTAC ternary complex kinetics, PROTAC degradation assays and ternary complex assays, PROTAC molecule design and synthesis, ADME & PK/PD studies of PROTAC molecules, and computer aided PROTAC design solutions; and XDC platforms, such as XDC conjugation and quality study, XDC chemistry research and development, and XDC functional studies. In addition, the company offers contract development and manufacturing services comprising integrated services for small molecule active pharmaceutical ingredients, formulation development and production services, and pharmaceutical analysis services, as well as CMC filing, global filing registration support, and other services. Further, it provides laboratory rental, and project management and bidding services, as well as sells compounds. The company was incorporated in 2008 and is headquartered in Shanghai, China.

About Zura Bio

Zura Bio Limited, a clinical-stage biotechnology company, focuses on developing novel medicines for immune and inflammatory disorders. It develops Tibulizumab, an IgG-scFv bispecific dual-antagonist antibody engineered by the fusion of ixekizumab and tabalumab that neutralizes IL-17A and BAFF, which is in Phase 2 clinical trial development; ZB-168, a monoclonal antibody that binds and neutralizes the IL-7 receptor chain that impact on diseases driven by IL7 and thymic stromal lymphopoietin immune pathways; and Torudokimab, a monoclonal antibody that neutralizes IL33, which is in Phase 2 clinical trial development. The company is based in Henderson, Nevada.